Skip to main content

Table 1 Relation between Bcl-2 status and other clinicopathological factors in patient groups with no adjuvant therapy or tamoxifen monotherapy

From: Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy

  No adjuvant therapy Tamoxifen monotherapy
Factors Bcl-2   P-value Bcl-2   P-value
  + (%) -   + (%) -  
Menopause    0.0049*    0.1249
Post 156 (58) 112   191 (64) 108  
Pre 210 (70) 92   117 (71) 48  
Tumor size   0.0023*   0.0051*
>20 mm 199 (58) 143   178 (61) 112  
≤20 mm 204 (70) 88   138 (74) 49  
Node   0.9049   0.2938
+ 96 (63) 56   141 (64) 80  
- 307 (64) 175   175 (68) 81  
Grade   <0.0001*   0.0040*
II + III 244 (54) 205   170 (61) 109  
I 157 (86) 26   145 (74) 52  
ER   <0.0001*   <0.0001*
+ 330 (88) 45   290 (74) 100  
- 71 (28) 186   26 (30) 61  
PR   <0.0001*   <0.0001*
+ 242 (89) 30   189 (76) 59  
- 159 (44) 200   127 (55) 102  
HER2   <0.0001*    0.0005*
+ 19 (21) 70   8 (33) 16  
- 381 (70) 160   308 (68) 145  
Total 634   477  
  1. *Significant, P < 0.05/7 = 0.0071 (Bonferroni adjustment)
  2. Post and Pre postmenopause and premenopause at the time of diagnosis, + positive, − negative, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2